Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)

被引：0

作者：

Bhattacharya, Seemana ^{[1
,2
]}

Mu, Hong ^{[1
,2
]}

Piya, Sujan ^{[1
,2
]}

Zhang, Weiguo ^{[1
,2
]}

McQueen, Teresa ^{[1
,2
]}

Paradiso, Linda ^{[3
]}

Oberkovitz, Galia ^{[4
]}

Benami, Eyal ^{[4
]}

Andreeff, Michael ^{[1
,2
]}

Borthakur, Gautam ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

[3] Strategia Therapeut Inc, 28420 Hardy Toll Rd,Suite 110, Spring, TX USA

[4] BioLineRx Ltd, Modiin Technol Pk 2,HaMaayan St, Modiin, Israel

来源：

关键词：

AML; FLT3-ITD; dual MEK1-FLT3 inhibitor; peptidic CXCR4-antagonist; leukemia-stroma interactions;

D O I：

10.1016/j.clml.2017.07.049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-033

引用

页码：S273 / S273

页数：1